Edwin Moses

Type: Person

Name: Edwin Moses

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Ablynx

Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF TH...

REGULATED INFORMATIONGHENT, Belgium, 8 May 2013 - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted ... [Published Investegate - May 08 2013]

Entities: Ablynx, KBC Asset Management NV, Nanobody

First reported May 07 2013 - Updated May 07 2013 - 1 reports

ABLYNX STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0962, AN ANTI-IgE NANOBODY, TO TREAT SEVERE ALLERGIC ASTHMA

- Ablynx [Euronext Brussels: ABLX] today announces that it has initiated pre-clinical development of its anti-IgE Nanobody®, ALX-0962, for the treatment of severe allergic asthma, with the goal of commencing Phase I clinical development in the second ... [Published Zecco - May 07 2013]

Entities: Ablynx, Nanobody, Xolair, Asthma

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Capital University

Fairborn boys relay squad team to beat

The Fairborn High School boys 4x400 relay put a special spin on its recent senior night during the Aukerman Relays.Then they did it again at last week's Edwin Moses/Dayton Relays."We were about as shocked as everyone else was," admitted senior Matt C ... [Published Individual.com - May 02 2013]

Entities: Jeremy Bridges, Fairborn High School, Lauren Wood, Capital University, Edwin Moses

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

Stillman College

National Physical Educators of the Year Announced at Educators Convention

- Honoring the elite of the physical activity, physical education and sport professions, the National Association for Sport and Physical Education (NASPE) announced the National Physical Education Teachers of the Year (TOY) for elementary, middle, and ... [Published Noodls - Apr 27 2013]

Entities: Stillman College, Elementary Middle School, Edwin Moses, Troy University, Central Washington University

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATIONGHENT, Belgium, 22 April 2013 - Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 22,686 common shares have been issued ... [Published Reuters - Apr 22 2013]

Entities: Ablynx, Nanobody, Edwin Moses, Belgium, Pulmonary Disease

Quotes

Dr Edwin Moses, Chairman and CEO of Ablynx commented: "we are very pleased to have initiated preclinical development of our anti-ige nanobody, which we expect to enter the clinic in the second half of next year. severe allergic asthma is an important condition and represents a substantial segment of the total asthma market that currently has a total value of $14.7 billion. due to the nanobody's unique and dual mode of action, we believe alx-0962 could take an important share of this very large market not least by offering a treatment option to patients not eligible for currently available ige inhibiting drugs."

Ablynx initiates preclinical development of treatment for allergic asthma [Published Individual.com - May 20 2013]

Commenting on today's update, Dr Edwin Moses, Chairman and CEO of Ablynx, said: "the highlight of the first quarter was the announcement in february of excellent phase iia efficacy and safety data for our anti-il-6r nanobody in rheumatoid arthritis patients. following these results, we started licensing discussions with a number of pharmaceutical companies. in parallel, we are also evaluating various possible scenarios for carrying out the next stage of clinical development of alx-0061 internally, as an alternative strategy for creating value." Financial review (1) including ?2.4 million restricted cash

ABLYNX ANNOUNCES Q1 2013 BUSINESS UPDATE [Published Noodls - May 15 2013]

More Content

sort by: Date \| Relevance
Ablynx initiates preclinical development of tre... [Published Individual.com - May 20 2013]
ABLYNX ANNOUNCES Q1 2013 BUSINESS UPDATE [Published Noodls - May 15 2013]
ABLYNX ANNOUNCES Q1 2013 BUSINESS UPDATE [Published Zecco - May 15 2013]
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE... [Published Investegate - May 08 2013]
Ablynx Starts Preclinical Development of ALX-09... [Published Pharma-Mag - May 08 2013]
ABLYNX STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0... [Published Zecco - May 07 2013]
Fairborn boys relay squad team to beat [Published Individual.com - May 02 2013]
National Physical Educators of the Year Announc... [Published Noodls - Apr 27 2013]
ABLYNX ANNOUNCES WARRANT EXERCISE [Published Reuters - Apr 22 2013]
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE... [Published Investegate - Apr 17 2013]

Blogs

sort by: Date \| Relevance
Ablynx Starts Preclinical Development of ALX-09... [Published Pharma-Mag - May 08 2013] Ablynx has announced that it has initiated preclinical development of its anti-IgE Nanobody, ALX-0962, for the treatment of severe allergic asthma, with the goal of commencing Phase I clinical development in the second half of 2014. ALX-0962 consists ...